Some ideas sound good in theory but just never manage to work out in
real-world experience, and cancer vaccines are on their way to that
destination. Following the failures of Vical and Merck KGaA with their respective cancer vaccines, GlaxoSmithKline (NYSE: GSK )
has announced the second pivotal trial failure for its MAGE-A3 cancer
vaccine. Glaxo will continue to try to identify patient sub-populations
in both melanoma and lung cancer that could/do respond to a clinically
significant degree, but the odds are good that this
high-risk/high-reward program is on its last legs.
Continue reading here:
Cancer Vaccines: Doomed to Fail?
No comments:
Post a Comment